Despite the Q4 revenue decline being due to one-time adjustments, the strong full-year growth and improved fundamentals suggest underlying business strength. The stock repurchase program and remediation of internal control weaknesses could boost investor confidence. Monitor the company's arbitration revenue sustainability and future guidance.
Price Chart
Executive Summary
Nutex Health reported strong full-year 2025 financial results with revenue up 82.4% year-over-year to $875.3 million and diluted EPS increasing to $10.48 from $9.69. Adjusted EBITDA surged 152.6% to $259.6 million. The company also announced a $25.0 million stock repurchase program. However, Q4 2025 revenue declined 41.1% due to a one-time $55 million arbitration true-up and prior-period revenue recognition.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue: $875.3 million (82.4% YoY growth)
- Full-year 2025 diluted EPS: $10.48 (up from $9.69 in 2024)
- Full-year 2025 Adjusted EBITDA: $259.6 million (152.6% YoY growth)
- Q4 2025 revenue decreased 41.1% to $151.7 million due to $55 million arbitration true-up
- Company remediated all material weaknesses in internal controls
- Authorized $25.0 million stock repurchase program
Financial Impact
Revenue increased by $395.3 million year-over-year, with Adjusted EBITDA growing by $156.8 million. The company generated $248.1 million in operating cash flow.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Hospital division | $844.2M | +188.0% |
| Population health management division | $31.1M | — |
Risk Factors
- Revenue heavily dependent on arbitration outcomes under the No Surprises Act
- High stock-based compensation ($117 million in 2025) could dilute shareholders
- Q4 2025 results show significant volatility in revenue recognition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-015174 |
| Document: nutx-20260305.htm | 0001628280-26-015174 |
| Document: 0001628280-26-015174-index-headers.html | 0001628280-26-015174 |
| Document: 0001628280-26-015174-index.html | 0001628280-26-015174 |
| Document: 0001628280-26-015174.txt | 0001628280-26-015174 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $191.25 | awaiting T+20 | — | $209.01 (+9.28%) |
Aug 13, 2026 10w ago | 8-K | $187.42 $217.02 | ▲ +15.79% | ▲ +17.78% | $209.01 (+11.52%) |
Aug 6, 2026 11w ago | Press Release | $162.07 $193.24 | ▲ +19.23% | ▲ +19.63% | $209.01 (+28.96%) |
Jul 21, 2026 13w ago | Press Release | $168.27 $187.66 | ▲ +11.52% | ▲ +8.96% | $209.01 (+24.21%) |
May 8, 2026 24w ago | Court Ruling | $132.88 $135.40 | ▼ −1.90% | ▼ −2.20% | $209.01 (−57.29%) |
Mar 13, 2026 32w ago | Insider Cluster | $88.80 $106.27 | ▲ +19.67% | ▲ +16.08% | $209.01 (+135.37%) |
Mar 5, 2026 33w ago | 8-K | $90.28 $100.65 | ▲ +11.49% | ▲ +13.53% | $209.01 (+131.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers